42 Global Ventures
42 Global Ventures
Supports companies in HealthTech, Life Sciences, and AgeTech sectors by helping them secure capital, build strategic partnerships, and scale internationally.
About
What does 42 Global Ventures do?
42 Global Ventures is a venture capital firm that focuses on supporting companies in the HealthTech, Life Sciences, and AgeTech sectors. They assist these companies in securing capital, building strategic partnerships, and scaling their operations internationally. Their work also centers on developing innovation ecosystems and supporting startups with fundraising, growth strategy, and deal-making.
Where is 42 Global Ventures headquartered?
42 Global Ventures is headquartered in Paris, France.
When was 42 Global Ventures founded?
42 Global Ventures was founded in 2025.
What industry does 42 Global Ventures operate in?
42 Global Ventures operates in HealthTech, Life Sciences, AgeTech.
AI-powered platform for healthcare providers to manage patient WhatsApp messages efficiently.
AI-powered platform for personalized weight management and health coaching.
Clinical Trial Discovery by ENSCORE.
An independent research reference providing accessible, accurate, and transparent information on bioactive peptides and peptide science.
Medbytes provides doctors with a personalized platform for high-impact medical research and news in their specialty.
SYLARIS™ offers premium wearable wellness patches and clinical-grade skincare designed for effortless, intentional, and beautifully designed self-care rituals.
Provider-supervised peptide therapy, NAD+ support, and cognitive enhancement for cellular renewal, recovery, and healthy aging.
Purpose-built WordPress plugins for healthcare and the agencies that serve them.
An entrant is a company tagged HealthTech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 6 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.